DCAT: Value Chain Insights — Tracking Expansions in High-Potency Manufacturing

In 2018, Recro added a 24,000-square-foot facility, which included space for processing highly potent compounds, near its existing 97,000-square-foot contract pharmaceutical development and manufacturing facility. The expansion provides capabilities including formulation and analytical development, clinical trial packaging, and commercial manufacturing for highly potent compounds. Read the article.

Want to know more?

Read the article

Back to Thought Leadership